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pitalization averaged $8,189 for moderate, $14,603 for
serious, $16,788 for severe, and $33,537 for critical TBI.
Costs also varied by injury type, averaging $20,084 for
gunshot wounds, $20,522 for motor-vehicle accidents,
$15,860 for falls, and $19,949 for blows to the head.
CONCLUSIONS: The economic burden of TBI in the
acute-care setting is substantial; treatment outcomes and
costs vary considerably by TBI severity and mechanism
of injury.
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Pharmaceutical care is known to help improve patient
quality of life, reduce adverse events and help reduce
healthcare costs.
OBJECTIVES: This paper aims to identify the current
level of cognitive pharmacy services that patients receive
in ambulatory pharmacy settings and the amount patients
are willing-to-pay for these services.
METHODS: A self-administered questionnaire was 
constructed and tested for validity. The questionnaire 
was distributed at two randomly selected ambulatory 
care pharmacies in Maryland. The instrument asked 
questions regarding demographics, current level of cog-
nitive pharmacy services the patient was receiving and 
the dollar amount the patient was willing-to-pay for the
service.
RESULTS: 91 people responded. Thirty-one percent of
the respondents were between the ages of 45 and 65 and
approximately 13% of the respondents were Hispanic.
The majority of the respondents were female (60%) and
about 33% had completed trade school or college. The
major insurance type was HMO/Medicare (41.8%) and
about 31.2% of respondents reported an annual income
between $20–30K. Sixty-three percent of respondents
reported a household size of two to four persons. Almost
80% of respondents reported their perceived health status
to be good/very good. Almost one-half (48.4%) of
respondents reported never receiving any detailed coun-
seling about their medications, and 60% of respondents
reported never receiving any monitoring services. The
respondents were willing-to-pay $0–10 (58.2%) and
$11–20 (29.7%) for a single pharmaceutical care evalu-
ation. The respondents were willing-to-pay $41–50
(16.5%) for a pharmaceutical care evaluation with a year
of monitoring by the pharmacist. Although, 36.3% of 
the respondents were only willing-to-pay between $0–10.
The majority of respondents reported that insurance 
companies should cover cognitive pharmacy services.
CONCLUSIONS: The results suggest that the majority of
the respondents are not receiving cognitive pharmacy ser-
vices; although, many of them would be willing-to-pay
for this type of service.
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OBJECTIVES: While pharmacoeconomic research is
often used as a tool to assist decision on product reim-
bursement, Budget Impact Analysis (BIA) is increasingly
required by decision-makers to ascertain the macro-
economic consequences of new product reimbursement 
in addition to proof of cost-effectiveness. BIA provides
insight into ﬁnancial consequences of reimbursing a new
technology. Poland is in the process of drafting country-
speciﬁc guidelines for BIA, positioned as complementary
to economic evaluation in decision making. The aim of
this study is to compare project of Polish BIA guidelines
with existing international guidance, highlighting areas of
agreement and dissent.
METHODS: Guidelines from ﬁve countries (Australia,
Canada, Netherlands, England & Wales, France, USA)
were reviewed, analyzed and comparison was under-
taken. The following areas were analysed: objective, 
use of BIA, responsibility in their conduct, target audi-
ence, methodology and ethical code of practice while 
conducting and in the publication of results. An analysis
of the differences between different national guide-
lines and their Polish counterparts was subsequently
undertaken.
RESULTS: Current international guidance for BIA is
limited, often unclear and variable in terms of deﬁning
what constitutes BIA and how it should be undertaken.
Australian PBAC guidelines for economic evaluation
provide most detail into how BIA should be undertaken
and reported. In comparison to existing guidance 
project of Polish BIA guidelines appears to be more
detailed and includes recommendations on perspective,
time horizon, reliability of data sources, reporting of
results, rates of adoption of new therapies, probability of
re-deploying resources. The intention was to establish
principles for best practice in designing and implement-
ing BIA.
CONCLUSIONS: Whilst there is an increased demand
for BIA, there is only limited guidance on how such
studies should be undertaken. It is hoped, that the Polish
guidelines can contribute to the development of such
analyses and deliver beneﬁt for Polish healthcare decision
makers and beyond.
